Short sellers vs the Clover Health (CLOV) share price: here’s my view

The Clover Health (CLOV) share price surged this month after becoming the next target of a short squeeze. Zaven Boyrazian takes a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Clover Health Investments (NASDAQ:CLOV) share price has seen some explosive growth recently. In fact, just over the first week of June, the US stock jumped by nearly 200%, from $7.64 to $22.15. It has since come down to around $15 today. But that is still around 50% higher than a year ago. What’s causing this sudden upward surge? And should I be considering Clover Health as a new addition to my portfolio?

The surging Clover Health (CLOV) share price

Before breaking down what’s going on with the CLOV share price, let’s take a look at the actual business. Clover Health is a Medicare Advantage health insurance company. The revenue model is pretty simple. Customers pay a monthly premium and should they ever need to visit the hospital, the bill is largely taken care of.

An insurance company wouldn’t be my first guess for a business capable of almost tripling in the space of a week, so what happened? It seems the Reddit army is at it again. Unless you’ve been living under a rock, you’ve probably heard of the meme stock movement that sent the share prices of companies like GameStop and AMC Entertainment through the roof, despite poor underlying fundamentals. These retail investors now have their sights locked on Clover Health, making the recent surge in the CLOV share price a result of yet another short squeeze.

Investigating what happened

Back in February this year, famous short-selling firm Hindenburg Research published a report against Clover Health with some pretty serious accusations. It proclaimed that Clover Health failed to disclose a Justice Department investigation when going public via a SPAC. It also accused Chamath Palihapitiya, a backer of the SPAC, of misleading investors when promoting the business.

Following this report, the Securities and Exchange Commission started an investigation. And since then, the volume of shares being sold short has climbed to around 36% today. With such a high short interest, retail investors adamantly started buying shares pushing the CLOV share price up to trigger a short squeeze.

But is this a case of a bad business being inflated by an internet frenzy? Maybe not. The management team has vehemently denied the accusations. CEO Vivek Garipalli described the report as “rife with ad hominem attacks, sweeping inaccuracies and gross mis-characterisations”. And so, giving the company the benefit of the doubt, is the underlying business worthy of its newly elevated valuation?

The Clover Health CLOV share price has its risks

The underlying business

Unlike other meme stocks, Clover Health does actually look healthy. It has a nearly insignificant amount of debt ($46m) on the balance sheet with plenty of cash ($405m) to spare. What’s more, the company has been successfully growing its customer base over the years, rising from 16,000 members in 2016 to over 66,000 as of the end of March this year. Combining this with a rapidly expanding revenue line makes the company appear to be somewhat undervalued, assuming growth can be maintained.

Having said that, I’m personally not interested in adding this business to my portfolio. Like many Medicare insurance providers, the bulk of the revenue actually comes from the US government, as most customers pay their premiums directly to Medicare.  Suppose the allegations by Hindenburg Research prove to have merit? In that case, it could embroil the business in expensive legal proceedings that would likely compromise the CLOV share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Clover Health Investments. The Motley Fool UK owns shares of Clover Health Investments. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »